Through the odds ratio (OR) calculations, the putative PARK2‐inactivating variants (including splicing, frameshift, CNVs, and predicted deleterious missense mutations) were strongly associated with melanoma risk when compared with control groups (OR = 3.95, 95% confidence interval = 1.34–15.75). Here, PRKN is linked to melanoma.